198 related articles for article (PubMed ID: 20922795)
21. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
22. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
23. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
24. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
[TBL] [Abstract][Full Text] [Related]
25. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
[TBL] [Abstract][Full Text] [Related]
26. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
[No Abstract] [Full Text] [Related]
27. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
[TBL] [Abstract][Full Text] [Related]
28. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Wadleigh M; Tefferi A
Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
[TBL] [Abstract][Full Text] [Related]
29. JAK2 inhibitors: are they the solution?
Santos FP; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
[TBL] [Abstract][Full Text] [Related]
30. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract][Full Text] [Related]
31. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Koopmans SM; Schouten HC; van Marion AM
Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
[TBL] [Abstract][Full Text] [Related]
33. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
[TBL] [Abstract][Full Text] [Related]
34. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
35.
Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
[TBL] [Abstract][Full Text] [Related]
36. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
Haybar H; Khodadi E; Shahjahani M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
39. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
40. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]